Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden
Denise A. Gococo-Benore, Justin J. Kuhlman, Ephraim E. Parent, Akash Sharma, Joseph Accurso, Ming Yang, A. Tuba Kendi, Geoffrey B. Johnson, Mohamad Bassam Sonbol, Timothy J. Hobday, Þorvarður R. Hálfdánarson, Jason S. Starr
Abstract
The aim of the current study was to describe the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden, defined as tumor involving more than 75% of the liver. <b>Methods:</b> We conducted a retrospective analysis of 371 patients who received at least 1 cycle of <sup>177</sup>Lu-DOTATATE at Mayo Clinic for advanced gastroenteropancreatic neuroendocrine tumors. We identified 15 total patients with more than 75% liver involvement on <sup>68</sup>Ga-DOTATATE PET/CT and with either a contrast-enhanced abdominal MRI or dual-phase abdominal CT examination. <b>Results:</b> Of the 15 patients with more than 75% liver involvement, 1 experienced hepatotoxicity (i.e., worsening liver enzymes or bilirubin) as defined by the Common Terminology Criteria for Adverse Events, version 5.0. No patients had grade 3–5 hepatotoxicity (i.e., clinical signs of liver failure). <b>Conclusion:</b> When considering the risk of liver injury from PRRT due to burden of disease, our data suggest that PRRT may be a safe option in patients with more than 75% liver involvement. Future efforts should be made to determine the safety profile of PRRT in patients with varying degrees of liver involvement.